Literature DB >> 26868115

Cementless total hip arthroplasty using Biolox®delta ceramic-on-ceramic bearing in patients with osteonecrosis of the femoral head.

Seung-Jae Lim1, Sang-Min Kim2, Dong-Wook Kim1, Young-Wan Moon1, Youn-Soo Park1.   

Abstract

PURPOSE: The purpose of this study was to evaluate the results of cementless total hip arthroplasty (THA) using a 32 mm or larger Biolox®delta ceramic-on-ceramic (CoC) bearing in patients with osteonecrosis of the femoral head after a minimum of 5 years of follow-up.
MATERIALS AND METHODS: We retrospectively analysed 44 patients (53 hips) who underwent cementless THA using Biolox®delta CoC bearing. There were 33 men (40 hips) and 11 women (13 hips) with the mean age of 49 years. A 36 mm head was used in 42 (79%) of 53 hips and a 32 mm head was used in 11 hips with smaller acetabular shells. The mean duration of follow-up was 5.3 years (range 5-6 years).
RESULTS: The mean Harris Hip Score improved from 50 points preoperatively to 97 points at final follow-up (p<0.001). All acetabular and femoral components showed radiographic evidence of osseointegration. No osteolysis was observed. No patients sustained ceramic fracture. An audible hip noise was identified in 2 (4%) of the 53 hips (1 squeaking and 1 clicking). Survivorship with revision for any reason at a minimum of 5 years was 100% in the best-case scenario and 95 % in the worst-case scenario.
CONCLUSIONS: The minimum 5-year results of cementless THA using a 32 mm or larger Biolox®delta CoC bearing in patients with osteonecrosis of the femoral head were encouraging with excellent survivorship. However, it was also found that the risk of noise development remains even for the new alumina matrix composite ceramic.

Entities:  

Mesh:

Year:  2016        PMID: 26868115     DOI: 10.5301/hipint.5000311

Source DB:  PubMed          Journal:  Hip Int        ISSN: 1120-7000            Impact factor:   2.135


  8 in total

1.  Third generation delta ceramic-on-ceramic bearing for total hip arthroplasty at mid-term follow-up.

Authors:  Alessandro Bistolfi; Riccardo Ferracini; Alessandro Aprato; Alessandro Massè; Walter Daghino; Sara Lea; Stefano Artiaco; Gwo-Chin Lee
Journal:  J Orthop       Date:  2020-08-28

2.  Outcome of Ceramic-on-Ceramic Total Hip Arthroplasty with 4th Generation 36 mm Head Compared to that with 3rd Generation 28 mm Head by Propensity Score Matching.

Authors:  Soong Joon Lee; Kang Sup Yoon
Journal:  Indian J Orthop       Date:  2020-09-02       Impact factor: 1.251

3.  Projections and Epidemiology of Revision Hip and Knee Arthroplasty in the United States to 2030.

Authors:  Andrew M Schwartz; Kevin X Farley; George N Guild; Thomas L Bradbury
Journal:  J Arthroplasty       Date:  2020-02-19       Impact factor: 4.757

Review 4.  Nontraumatic Osteonecrosis of the Femoral Head: Where Do We Stand Today?: A 5-Year Update.

Authors:  Michael A Mont; Hytham S Salem; Nicolas S Piuzzi; Stuart B Goodman; Lynne C Jones
Journal:  J Bone Joint Surg Am       Date:  2020-06-17       Impact factor: 6.558

5.  Short stem total hip arthroplasty for osteonecrosis of the femoral head in patients 60 years or younger: a 3- to 10-year follow-up study.

Authors:  Antonio Capone; Fabrizio Bienati; Stefania Torchia; Daniele Podda; Giuseppe Marongiu
Journal:  BMC Musculoskelet Disord       Date:  2017-07-17       Impact factor: 2.362

6.  Squeaking in fourth-generation ceramic-on-ceramic total hip replacement and the relationship with prosthesis brands: meta-analysis and systematic review.

Authors:  Chen-Chen Zhao; Guo-Xin Qu; Shi-Gui Yan; Xun-Zi Cai
Journal:  J Orthop Surg Res       Date:  2018-06-01       Impact factor: 2.359

Review 7.  Updates in biomaterials of bearing surfaces in total hip arthroplasty.

Authors:  Ahmed A Khalifa; Hatem M Bakr
Journal:  Arthroplasty       Date:  2021-11-01

8.  Outcomes of Total Hip Arthroplasty in Patients with Osteonecrosis of the Femoral Head Following Surgical Treatment of Brain Tumors.

Authors:  Seung-Jae Lim; Chan-Woo Park; Dong-Uk Kim; Kwangjoon Han; Minkyu Seo; Young-Wan Moon; Jung-Il Lee; Youn-Soo Park
Journal:  J Clin Med       Date:  2019-10-16       Impact factor: 4.241

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.